How can we help you?
Modern mass spectrometry developments hold significant potential for the discovery and sensitive detection of innovative (sets of) biomarkers which will allow rapid and accurate diagnosis of multiple disorders simultaneously in a single patient’s small-volume sample.
ProteoFormiX is running a top-down proteomics-based translational biomarker discovery platform. We employ state-of-the-art and proprietary technology to identify disease-associated proteoforms (e.g., peptides) in clinically sampled human tissues and biofluids.
Founder and industry support
ProteoFormiX was founded by Prof. Dr. Peter Verhaert in 2017. The company resides at JLABS@BE, the European Johnson & Johnson Innovation Center. ProteoFormiX is supported by BlueHealth Innovation, EIT Health, Flanders Innovation and Entrepreneurship (VLAIO) and Imec.istart.
“The value of the extensive incubator management expertise offered by Bioqube Ventures, along with direct access to the largest European Life Science R&D ecosystem based at the Janssen campus in Beerse is priceless for a start-up like ProteoFormiX.”
If you wish to get in touch with us at ProteoFormiX, send us an e-mail through contact[at]proteoformix.com or try our contact page.